We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
SWISS LAW AND TAX
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
24 September 2018
CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced on September 20, 2018 the pricing of a public offering of 4,210,526 of its shares at an offering price of $47.50 per share. The gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, are estimated to be approximately $200 million.
Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Guggenheim Securities, LLC and Needham & Company, LLC are acting as co-managers for the offering. Goodwin Procter LLP advises CRISPR Therapeutics as to US law, VISCHER AG as to Swiss law. The team at VISCHER is led by Matthias Staehelin (Partner) with Angelo Imperiale (Associate), both Corporate.
Categories: Corporate and commercial, Life Sciences, Pharma, Biotech, Deals & Cases
Attorney at Law and Civil Law Notary (BS/BL)
Oculis Holding AG (Nasdaq: OCS) completed a financing of approximately $59 million, consisting of...
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...